EMA: Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development.

The increasing knowledge of variation within the human genome is being used for the development of personalised and stratified medicine, with the aims of decreasing the number of adverse drug reactions and increasing the efficacy of drug therapy. Significant pharmacogenomic research has focused on biomarkers (BMs) that identify individuals at risk.